-+ 0.00%
-+ 0.00%
-+ 0.00%

Bicycle Therapeutics posts corporate presentation outlining Bicycle molecule platform and oncology pipeline

PUBT·06/01/2026 13:56:12
Listen to the news
Bicycle Therapeutics posts corporate presentation outlining Bicycle molecule platform and oncology pipeline
  • Bicycle Therapeutics outlined an oncology-focused pipeline built on its Bicycle molecule platform, aiming to deliver payloads to hard-to-drug targets.
  • Lead program nuzefatide pevedotin, an EphA2-targeting Bicycle drug conjugate, is in a Phase 2 open-label trial in second-line or later pancreatic cancer.
  • Presentation highlighted safety data in 161 exposed patients, citing no hemorrhage events to date and no Grade 3 peripheral neuropathy reported.
  • Cash and cash equivalents totaled USD 559.5 million as of March 31, 2026, with expected financial runway into 2030.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.